Tan et al recently published their meta-analysis of observational studies of patients undergoing treatment of acne with isotretinoin. Their study was published in JAMA Dermatology. In addition to the primary article, there is also an editorial which summarises the study findings, strengths and limitations. The FDA has had a black box warning since 2005 citing the risk of suicide, depression, aggression and psychosis with isotretinoin, although this has been contentious. The main conclusion of the current study was that at a population level there is no increased risk of suicide or other psychiatric conditions, but that on an individual level clinicians should take due care in ensuring the psychological well-being of their patients on isotretinoin.

Read the full article here.